| Health / Medical Topics |
gp100: ES209-217(210M) Peptide
A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth. (NCI Thesaurus)
YOU MAY ALSO LIKE
Tumor infiltrating lymphocytes (TIL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to the…
Human peripheral blood lymphocytes (PBL) isolated from a patient, exposed to the tumor-associated antigen gp100 in vitro, and then transferred back to…
Peripheral blood lymphocytes (PBL) harvested from host blood and stimulated in vitro with tumor-specific gp 100 antigen. 'Pulsing' PBL with gp100, a…
A cancer vaccine comprised of a recombinant fowlpox virus vector encoding the melanoma antigen glycoprotein 100 (gp 100) with potential antineoplastic…
A cancer vaccine consisting of a recombinant vaccinia virus encoding the gp100 melanoma-melanocyte antigen. gp100 human antigen is a wild-type self-antigen expressed…
A recombinant peptide derived from the human melanoma antigen glycoprotein 100 (gp100) with potential use in cancer immunotherapy. gp100 protein(184V) has a…
